EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial

Elliot B Tapper, Beanna Martinez, Peter Jepsen iD, Xi Chen, Neehar D Parikh iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.18127 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, 2024. Written by Elliot B Tapper and 4 co-authors. Institution: Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA. Major MEDLINE topics: Liver Cirrhosis, Diphosphonates, Bone Density Conservation Agents, Osteoporosis. Cited 8 times so far (Crossref); 25 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIDDK NIH HHS.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Falls and fractures are common and morbid for patients with cirrhosis. Bisphosphonates are recommended for the prevention of fractures for people with osteoporosis cirrhosis; however, data supporting effectiveness in cirrhosis are lacking.

Aim

We sought to emulate a clinical trial of bisphosphonates in cirrhosis.

Methods

We used national Medicare data (2008–2020) to examine the 5‐year risk of fractures in patients who did or did not receive bisphosphonates with a new‐user design among people diagnosed with cirrhosis and osteoporosis. We balanced treated and untreated with inverse probability of treatment weighting, evaluated intention‐to‐treat and as‐treated effects, and examined both control exposures (statin use) and outcomes (decompensation) to test causal relationships.

Results

There were 253 and 20,888 new users and non‐users of bisphosphonates, respectively. The median age was 74 years. The most common bisphosphonate used was alendronate (73.6%). Bisphosphonates significantly reduced fractures overall (27.5% vs. 33.0%, p = 0.0004) in the intention‐to‐treat analysis, particularly for people

Subjects

MeSH terms (MEDLINE)

Liver CirrhosisDiphosphonatesBone Density Conservation AgentsOsteoporosisHumansMaleFemaleAgedUnited StatesAged, 80 and overMedicareOsteoporotic FracturesTreatment OutcomeFractures, BoneMiddle AgedAccidental FallsAlendronate

Substances

DiphosphonatesBone Density Conservation AgentsAlendronate

Authors and institutions

  • Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.
  • Department of Hepatology & Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Medicine, University of Aarhus, Aarhus, Denmark.

ORCID profiles: Peter Jepsen, Neehar D Parikh

Funding

  • NIDDK NIH HHS

Cite

APA

Tapper, E. B., Martinez, B., Jepsen, P., Chen, X., & Parikh, N. D. (2024). Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18127

Vancouver

Tapper EB, Martinez B, Jepsen P, Chen X, Parikh ND. Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18127

BibTeX
@article{Tapper2024,
  author = {Tapper, Elliot B and Martinez, Beanna and Jepsen, Peter and Chen, Xi and Parikh, Neehar D},
  title = {Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.18127}
}
Start for free →